In a previous study we demonstrated that the FOXO1-Androgen Receptor interaction in the liver of the testosterone treated male T2DM mice inhibited the gluconeogenic action of FOXO1, decreasing the PEPCK levels, thereby reducing fasting BGL, despite an increased hepatic insulin resistance [9]. Here, INS is linked to type 2 diabetes mellitus.